IKT

Inhibikase Therapeutics, Inc. NCM · IKT

$2.17 -0.06 (-2.69%)

Extended · +1.10σ

+ Compare Open in Sniper

Mkt cap $0.3B

P/E —

Day $2.15 – $2.25

52wk $1.49 – $2.36

Avg vol 0.8M

Beta 0.94

Div yld —

Next earnings 2026-05-12

Quick read

At a glance

Inhibikase Therapeutics, Inc.

IKT last traded at $2.17, down 2.7% on the day; that's in the upper part of its 52-week range ($1.49–$2.36). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.

The next scheduled earnings report (2026-05-12) is the biggest known catalyst on the calendar, and after a strong run, watch whether the price can hold its gains on quieter days.

A quick snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

Price is stretched slightly above its normal range — a light stretch — early days, worth watching.

Long —

Setup score 16 / 100

Price is sitting close to its normal range — no real dip to buy yet.

· Aligned with breakout up (strong tailwind)

Technical read: above KC1 lower, +1.12 ATR from EMA21 · no notable pattern

What it means: Price is sitting close to its normal range — no real dip to buy yet. The trigger bar shows no standout candle signal yet.

Score split: chart signals 16 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 16 pts

Cycle position 6

Market fit 10

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

Setup score 20 / 100

Price is stretched slightly above its normal range — a light stretch — early days, worth watching.

· KC1 upper stretch — light pop
· RSI hook from overbought (65)
· Counter-trend short in breakout up

Technical read: KC1 upper, +1.12 ATR from EMA21 · no notable pattern

What it means: Price is stretched slightly above its normal range — a light stretch — early days, worth watching. The trigger bar shows no standout candle signal yet.

Score split: chart signals 20 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 20 pts

Cycle position 14

Momentum 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

The model's verdict is “Unknown” and accounting quality screens as Adequate. Model estimates only — do your own due diligence.

Unknown Accounting: Adequate

Accounting quality Adequate

✓ More cash than debt
✓ Current ratio 21.70 (antifragile)
✓ Debt/equity 0.05 (antifragile)

⚠ Negative retained earnings

Key statistics

All statistics →

IKT is a $341 million company.

Market cap $0.3B

P/E ttm —

Beta 0.94

52w range $1.49 – $2.36

Avg volume 0.8M

Dividend yield —

Sector Healthcare

Next earnings 2026-05-12

52-week range · today's price

$1.49$2.36

More on IKT

Earnings

See more →

Last reported: 2026-03-26
EPS (act / est): -0.09 / -0.12
Surprise: +23.9%
Next report: 2026-08-13

About

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel …